clinical trials

News

After ph3 win, Roche eyes earlier use of Columvi in DLBCL

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting

Patients

The case for adaptive EDI strategies in the UK

Clinical research in the UK is on a mission to ensure everyone, regardless of who they are, can participate.

News

Ionis, Arrowhead hail data with triglyceride drugs at ACC

Drugs from Ionis and Arrowhead Pharma that block apolipoprotein C-III (apoC-III) have shown their value in treating diseases associated with elevated triglyceride levels i

News

Jardiance doesn’t cut it in post-heart attack trial

SGLT2 inhibitors have transformed the treatment of heart failure in the last few years, but an attempt to extend their use into the setting of post-heart attack patients h

News

ADRIATIC buoys Imfinzi’s prospects in early lung cancer

After a setback in a trial of Imfinzi in early non-small cell lung cancer (NSCLC) last year, AstraZeneca has clawed back some ground with a positive result in small-cell l

News

Trial finds benefit for GLP-1 agonist in Parkinson’s

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for t

After ph3 win, Roche eyes earlier use of Columvi in DLBCL

The case for adaptive EDI strategies in the UK

Ionis, Arrowhead hail data with triglyceride drugs at ACC

Jardiance doesn’t cut it in post-heart attack trial

ADRIATIC buoys Imfinzi’s prospects in early lung cancer

Trial finds benefit for GLP-1 agonist in Parkinson’s

LSX2026: Addressing adult eye cancer, with Roi Raz

Using AI-driven synthetic personas to take your insights fur...

clinical trials

Editor's Picks